Living donor liver transplantation to patients with hepatitis C virus cirrhosis.
Living donor liver transplantation (LDLT) is an alternative therapeutic option for patients with end-stage hepatitis C virus (HCV) cirrhosis because of the cadaveric organ shortage. HCV infection is now a leading indication for LDLT among adults worldwide, and there is a worse prognosis with HCV recurrence. The antivirus strategy after transplantation, however, is currently under debate. Recent updates on the clinical and therapeutic aspects of living donor liver transplantation for HCV are discussed in the present review.
Sugawara
Yasuhiko
Y
Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. yasusuga-tky@umin.ac.jp
Makuuchi
Masatoshi
M
D000998:Antiviral Agents / Q000627:therapeutic use; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008099:Liver / Q000473:pathology / Q000601:surgery / Q000821:virology; D008103:Liver Cirrhosis / Q000473:pathology / Q000601:surgery* / Q000821:virology*; D016031:Liver Transplantation / Q000379:methods / Q000639:trends*; D019520:Living Donors; D011183:Postoperative Complications / Q000821:virology; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D055502:Secondary Prevention; D009927:Tissue and Organ Procurement
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin